<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902951</url>
  </required_header>
  <id_info>
    <org_study_id>18-001037</org_study_id>
    <secondary_id>NCI-2019-00337</secondary_id>
    <nct_id>NCT03902951</nct_id>
  </id_info>
  <brief_title>Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer</brief_title>
  <official_title>A Single-Arm, Open-Label, Phase II Study of Systemic and Tumor Directed Therapy for Recurrent Oligometastatic M1 Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Janssen Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Jonsson Comprehensive Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II trial studies how well antiandrogen therapy (leuprolide, apalutamide, and&#xD;
      abiraterone acetate) and stereotactic body radiation therapy (SBRT) works in treating&#xD;
      patients with prostate cancer that has come back and has spread to other parts of the body.&#xD;
      Drugs used in chemotherapy, such as leuprolide, apalutamide, and abiraterone acetate, work in&#xD;
      different ways to stop the growth of tumor cells, either by killing the cells, by stopping&#xD;
      them from dividing, or by stopping them from spreading. SBRT uses special equipment to&#xD;
      position a patient and deliver radiation to tumors with high precision. This method can kill&#xD;
      tumor cells with fewer doses over a shorter period and cause less damage to normal tissue.&#xD;
      Giving antiandrogen therapy and SBRT may work better in treating patients with prostate&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess the efficacy of combined systemic and tumor directed therapy for recurrent&#xD;
      oligometastatic M1a,b prostate cancer patients with 1-5 metastases (exclusive of pelvic nodal&#xD;
      N1 metastases) staged by prostate-specific membrane antigen (PSMA) positron emission&#xD;
      tomography (PET)-computed tomography (CT).&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. Time to biochemical progression. II. Time to additional antineoplastic therapy. III.&#xD;
      Prostate cancer specific survival. IV. Safety and tolerability. V. Assessment of health&#xD;
      related quality of life using the Functional Assessment of Cancer Therapy - Prostate (FACT-P)&#xD;
      scale.&#xD;
&#xD;
      CORRELATIVE OBJECTIVES:&#xD;
&#xD;
      I. To determine genomic and transcriptomic features present in metastatic tumors in patients&#xD;
      that respond to this multimodal therapy.&#xD;
&#xD;
      II. To evaluate biomarkers of response using circulating tumor cells (CTCs). III. To evaluate&#xD;
      biomarkers of response using circulating tumor deoxyribonucleic acid (DNA) (ctDNA).&#xD;
&#xD;
      IV. To evaluate immunophenotypes of circulating immune cells.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
      Patients receive a single dose of leuprolide subcutaneously (SC) on day 1 and apalutamide&#xD;
      orally (PO) once daily (QD) and abiraterone acetate PO QD for up to 6 months in the absence&#xD;
      of disease progression or unacceptable toxicity. Beginning 2 months of initiation of&#xD;
      antiandrogen therapy (ADT), patients also receive SBRT over 1, 3, or 5 fractions in the&#xD;
      absence of disease progression or unacceptable toxicity.&#xD;
&#xD;
      After completion of study treatment, patients are followed up within 2 -4 weeks, every 30&#xD;
      days for 6 months, and then every 3 months thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 24, 2020</start_date>
  <completion_date type="Anticipated">January 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of patients achieving a serum prostate specific antigen (PSA) of &lt; 0.05 ng/mL</measure>
    <time_frame>Up to 6 months post treatment</time_frame>
    <description>Will be summarized by count and percent along with the 95% confidence interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to biochemical progression</measure>
    <time_frame>Baseline to first rise in PSA to 0.2 ng/mL, assessed up to 2 years</time_frame>
    <description>Will be summarized using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to radiographic progression</measure>
    <time_frame>Baseline to time when any imaging shows new evidence of metastatic disease, assessed up to 2 years</time_frame>
    <description>Will be summarized using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to initiation of alternative antineoplastic therapy</measure>
    <time_frame>Baseline to time when new anti-prostate cancer therapy is initiated, assessed up to 2 years</time_frame>
    <description>Will be summarized using Kaplan-Meier method.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prostate cancer specific survival</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health related quality of life: Functional Assessment of Cancer Therapy - Prostate (FACT-P) scale - patient questionnaire</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
    <description>This uses the Functional Assessment of Cancer Therapy - Prostate (FACT-P) questionnaire. It assesses patient function in four domains: Physical, Social/Family, Emotional, and Functional well-being, which is further supplemented by 12 site specific items to assess for prostate related symptoms. Items are rated on a 0 to 4 Likert type scale and combined to produce subscale scores for each domain and a global score, the higher the score, the better the quality of life. Range from 0-150 . Data will be aggregated per patient and over time.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 30 days post treatment</time_frame>
    <description>The intensity of clinical adverse events will be graded according to the Common Terminology Criteria for Adverse Events version (v) 4.0 (CTCAE) grading system in the toxicity categories.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarker analysis</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
    <description>Will conduct whole exome deep sequencing (WES), RNA sequencing (RNA-seq), and comparative genomic hybridizations (CGH) of the metastatic tumors.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Genomic and transcriptomic features present in metastatic tumors</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
    <description>Will conduct whole exome deep sequencing (WES), ribonucleic acid (RNA) sequencing (RNA-seq), and comparative genomic hybridizations (CGH) of the metastatic tumors of the 28 patients enrolled in the Phase II trial. Then, will identify discriminating features of the metastatic tumors in responders that distinguish them from the non-responders.</description>
  </other_outcome>
  <other_outcome>
    <measure>Circulating tumor deoxyribonucleic acid (ctDNA) for predictors of response</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Circulating tumor cells (CTCs) for predictors of response</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in circulating immunophenotypes</measure>
    <time_frame>Baseline up to 2 years post treatment</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Metastatic Prostate Adenocarcinoma</condition>
  <condition>Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation</condition>
  <condition>Recurrent Prostate Carcinoma</condition>
  <condition>Stage IVB Prostate Cancer AJCC v8</condition>
  <arm_group>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive leuprolide SC on day 1, Patients receive a single dose of leuprolide SC on day 1 and apalutamide PO QD and abiraterone acetate PO QD for up to 6 months in the absence of disease progression or unacceptable toxicity. Beginning 2 months of initiation of ADT, patients also receive SBRT over 1, 3, or 5 fractions in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone Acetate</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <other_name>CB7630</other_name>
    <other_name>Zytiga</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apalutamide</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <other_name>ARN 509</other_name>
    <other_name>ARN-509</other_name>
    <other_name>ARN509</other_name>
    <other_name>JNJ 56021927</other_name>
    <other_name>JNJ-56021927</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leuprolide Acetate</intervention_name>
    <description>Given SC</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <other_name>A-43818</other_name>
    <other_name>Abbott 43818</other_name>
    <other_name>Abbott-43818</other_name>
    <other_name>Carcinil</other_name>
    <other_name>Depo-Eligard</other_name>
    <other_name>Eligard</other_name>
    <other_name>Enanton</other_name>
    <other_name>Enantone</other_name>
    <other_name>Enantone-Gyn</other_name>
    <other_name>Ginecrin</other_name>
    <other_name>LEUP</other_name>
    <other_name>Leuplin</other_name>
    <other_name>Leuprorelin Acetate</other_name>
    <other_name>Lucrin</other_name>
    <other_name>Lucrin Depot</other_name>
    <other_name>Lupron</other_name>
    <other_name>Lupron Depot</other_name>
    <other_name>Lupron Depot-3 Month</other_name>
    <other_name>Lupron Depot-4 Month</other_name>
    <other_name>Lupron Depot-Ped</other_name>
    <other_name>Procren</other_name>
    <other_name>Procrin</other_name>
    <other_name>Prostap</other_name>
    <other_name>TAP-144</other_name>
    <other_name>Trenantone</other_name>
    <other_name>Uno-Enantone</other_name>
    <other_name>Viadur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Quality-of-Life Assessment</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <other_name>Quality of Life Assessment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire Administration</intervention_name>
    <description>Ancillary studies</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Stereotactic Body Radiation Therapy</intervention_name>
    <description>Undergo SBRT</description>
    <arm_group_label>Treatment (leuprolide, apalutamide, abiraterone acetate, SBRT)</arm_group_label>
    <other_name>SABR</other_name>
    <other_name>SBRT</other_name>
    <other_name>Stereotactic Ablative Body Radiation Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Confirmed diagnosis of prostate adenocarcinoma after radical prostatectomy (primary&#xD;
             small cell carcinoma of the prostate is not allowed, however adenocarcinoma with&#xD;
             neuroendocrine differentiation is allowed)&#xD;
&#xD;
          -  Presence of 1-5 visible metastases (by PSMA PET-CT)&#xD;
&#xD;
               -  At least one metastasis must be M1a-b&#xD;
&#xD;
               -  Visceral metastases are not allowed&#xD;
&#xD;
               -  Patients may have any number of pelvic nodal metastases (but largest must be &lt; 2&#xD;
                  cm)&#xD;
&#xD;
               -  Metastases must be amenable to treatment with SBRT&#xD;
&#xD;
               -  Biopsy of one metastasis must be attempted, unless unsafe to perform&#xD;
&#xD;
          -  Patient must be fit to undergo SBRT to all visible sites of metastases, ADT&#xD;
&#xD;
          -  Total testosterone &gt; 150 ng/dL prior to ADT (optimal time to measure total&#xD;
             testosterone is between 8 and 9 am)&#xD;
&#xD;
          -  Adequate performance status (Eastern Cooperative Oncology Group [ECOG] 0-1)&#xD;
&#xD;
          -  Hemoglobin &gt;= 9.0 g/dL, independent of transfusion and/or growth factors within 3&#xD;
             months prior to randomization&#xD;
&#xD;
          -  Platelet count &gt;= 100,000 x 10^9/uL independent of transfusion and/or growth factors&#xD;
             within 3 months prior to randomization&#xD;
&#xD;
          -  Serum albumin &gt;= 3.0 g/dL&#xD;
&#xD;
          -  Glomerular filtration rate (GFR) &gt;= 45 mL/min&#xD;
&#xD;
          -  Serum potassium &gt;= 3.5 mmol/L&#xD;
&#xD;
          -  Serum total bilirubin =&lt; 1.5 x upper limits of normal (ULN)&#xD;
&#xD;
               -  Note: In subjects with Gilbert?s syndrome, if total bilirubin is &gt; 1.5 x ULN,&#xD;
                  measure direct and indirect bilirubin and if direct bilirubin is =&lt; 1.5 x ULN,&#xD;
                  subject may be eligible&#xD;
&#xD;
          -  Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &lt; 2.5 x ULN&#xD;
&#xD;
          -  Medications known to lower the seizure threshold must be discontinued or substituted&#xD;
             at least 4 weeks prior to study entry&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any evidence of spinal cord compression (radiological or clinical)&#xD;
&#xD;
          -  Prior pelvic malignancy&#xD;
&#xD;
          -  Prior pelvic radiation aside from salvage prostate radiation&#xD;
&#xD;
          -  Concurrent malignancy aside from superficial skin cancers or superficial bladder&#xD;
             tumors&#xD;
&#xD;
          -  Inability to undergo radiotherapy, or ADT&#xD;
&#xD;
          -  Primary small cell carcinoma of the prostate (prostate adenocarcinoma with&#xD;
             neuroendocrine differentiation is allowed)&#xD;
&#xD;
          -  Inflammatory bowel disease or active collagen vascular disease&#xD;
&#xD;
          -  History of any of the following:&#xD;
&#xD;
               -  Seizure or known condition that may pre-dispose to seizure (e.g. prior stroke&#xD;
                  within 1 year to randomization, brain arteriovenous malformation, Schwannoma,&#xD;
                  meningioma, or other benign central nervous system [CNS] or meningeal disease&#xD;
                  which may require treatment with surgery or radiation therapy)&#xD;
&#xD;
               -  Severe or unstable angina, myocardial infarction, symptomatic congestive heart&#xD;
                  failure, arterial or venous thromboembolic events (eg, pulmonary embolism,&#xD;
                  cerebrovascular accident including transient ischemic attacks), or clinically&#xD;
                  significant ventricular arrhythmias within 6 months prior to randomization&#xD;
&#xD;
          -  Current evidence of any of the following:&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
               -  Gastrointestinal disorder affecting absorption&#xD;
&#xD;
               -  Active infection (eg, human immunodeficiency virus [HIV] or viral hepatitis)&#xD;
&#xD;
               -  Any chronic medical condition requiring a higher dose of corticosteroid than 10&#xD;
                  mg prednisone/prednisolone once daily&#xD;
&#xD;
               -  Any condition that in the opinion of the investigator would preclude&#xD;
                  participation in this study&#xD;
&#xD;
               -  Concomitant strong CYP3A4 inducers. (If a strong CYP3A4 inducer must be&#xD;
                  co-administered, abiraterone acetate dose frequency will be adjusted). [SAFETY:&#xD;
                  Warning against use with CYP2C8 inhibitors with narrow therapeutic index is also&#xD;
                  pertinent to be included as it is also part of United States Prescribing&#xD;
                  Information (USPI): In a CYP2C8 drug-drug interaction trial in healthy subjects,&#xD;
                  the area under curve (AUC) of pioglitazone (CYP2C8 substrate) was increased by&#xD;
                  46% when pioglitazone was given together with a single dose of 1,000 mg&#xD;
                  abiraterone acetate. Therefore, patients should be monitored closely for signs of&#xD;
                  toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used&#xD;
                  concomitantly with ZYTIGA]&#xD;
&#xD;
               -  Treatment with CYP2D6 substrates that have a narrow therapeutic index. If an&#xD;
                  alternative treatment cannot be used, a dose reduction of the CYP2D6 substrate&#xD;
                  may be considered&#xD;
&#xD;
               -  Baseline moderate and severe hepatic impairment (ChildPugh Class B &amp; C)&#xD;
&#xD;
          -  Presence of visceral metastases (i.e., stage M1c)&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Nickols</last_name>
    <role>Principal Investigator</role>
    <affiliation>UCLA / Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Margaret A Bradley</last_name>
    <phone>310-794-3452</phone>
    <email>mabradley@mednet.ucla.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Vincent Basehart</last_name>
    <phone>310-267-8954</phone>
    <email>vbasehart@mednet.ucla.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>UCLA / Jonsson Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Basehart</last_name>
      <phone>310-267-8954</phone>
      <email>vbasehart@mednet.ucla.edu</email>
    </contact>
    <contact_backup>
      <last_name>Margaret A Bradley</last_name>
      <phone>310-794-3452</phone>
      <email>mabradley@mednet.ucla.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Nicholas Nickols, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 3, 2019</study_first_submitted>
  <study_first_submitted_qc>April 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>August 10, 2021</last_update_submitted>
  <last_update_submitted_qc>August 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leuprolide</mesh_term>
    <mesh_term>Abiraterone Acetate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

